MedTrace Logo

Supra-early Post-Surgery Chemotherapy in the Treatment on GBM Patients

NCT02520635 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 180

Last updated 2019-07-11

No results posted yet for this study

Summary

The primary purpose of the study is to evaluate the efficacy and safety of supra-early post-surgery chemotherapy versus standard TEMODAL® regimen in treatment of patients with newly diagnosed glioblastoma multiforme. The secondary purpose is to assess the efficacy of supra-early post-surgery chemotherapy in release brain edema.

Conditions

Interventions

DRUG

supra-early TEMODAL® chemotherapy

DRUG

standard TEMODAL® chemotherapy

RADIATION

Radiotherapy 60Gy

Sponsors & Collaborators

  • Beijing Tiantan Hospital

    lead OTHER

Principal Investigators

  • Song Lin, MD · Beijing Tiantan Hospital

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-01-31
Primary Completion
2020-12-31
Completion
2020-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02520635 on ClinicalTrials.gov